Thursday, June 25, 2020
In this episode, Dr. Richard Childs, a senior investigator and Clinical Director of the National Heart, Lung, and Blood Institute (NHLBI), recounts his experience using the antiviral remdesivir to treat patients with COVID-19 in one of the early hot zones of the pandemic. He led a team sent to care for passengers on the Diamond Princess cruise ship that was held in quarantine in Yokohama, Japan at the start of the outbreak. Since then, remdesivir has continued to gain traction as a possible standard of care. Dr. Matthew Hall, biology group leader at the National Center for Advancing Translational Sciences (NCATS), explains the development of the drug and its newfound purpose in the battle against the novel coronavirus.
Thursday, May 21, 2020
Perhaps now more than ever, it is undeniable how integral vaccines have become to public health. Vaccines protect us from a whole host of infectious diseases, including chickenpox, measles and the seasonal flu. With a new threat at hand, scientists at the NIH swiftly developed a vaccine candidate against the novel coronavirus that causes COVID-19. The pre-clinical effort was driven in part by Dr. Kizzmekia Corbett, a viral immunologist and research fellow in the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID).
Wednesday, April 15, 2020
Social distancing is the best way to curtail the spread of COVID-19, but if innumerable days of isolation start to feel like they’re taking a toll on your mental welfare, there might be some solace waiting in the kitchen. According to mental health experts, cooking can reduce anxiety and alleviate mental distress. Dr. Nicole Farmer is a clinical researcher studying many facets of how diet affects human biology and behavior, including the effects of cooking interventions on mental well-being.
Monday, February 24, 2020
Radioactive drugs carry radioactive substances that can be engineered to specifically target and kill tumor cells inside the body. In 2018, the FDA approved a radioactive drug called Lutathera to treat tumors that affect the pancreas or gastrointestinal tract. Now, scientists at the NIH led by Dr. Frank Lin are testing whether Lutathera can also be effective against rare tumors of the adrenal glands. Dr. Lin is a clinician and researcher focused on bringing radioactive drugs — also known as radionuclides — from bench to bedside. His work could accelerate the development of new therapies for patients with rare cancers who have few or no other treatment options.
Monday, January 27, 2020
The neurons in our brains use both electrical and chemical signals to communicate. When those signals are not generated or interpreted correctly, serious problems can arise. Dr. Jerry Yakel is a neurobiologist studying acetylcholine receptors, which allow neurons to turn signals transmitted using the chemical acetylcholine into electrical messages. Because acetylcholine receptors are found on so many nerve cells, numerous neurological disorders can arise when they fail to work properly, including Alzheimer’s, Parkinson’s, and epilepsy. By studying these receptors, Dr. Yakel’s team hopes to better understand how they contribute to disease, which could eventually lead to therapies for a variety of neurological conditions.
Monday, December 9, 2019
Anybody who observes a person with a neurological illness like Tourette syndrome or schizophrenia can clearly see how these conditions affect behavior. What’s much more difficult to determine is how these ailments relate to changes in the brain. Dr. Armin Raznahan is a child psychiatrist who uses a genetics-first approach and state-of-the-art neuroimaging tools to examine how the size and shape of the brain differ in children and adolescents with neuropsychiatric disorders compared to healthy individuals. His discoveries about these illnesses could ultimately improve our ability to identify and treat people who have them, as well as predict which children might develop them.
Monday, November 18, 2019
Our houses, workplaces, and even the air we breathe are teeming with microbes, some of which can cause severe illness. Dr. Catharine Bosio is an immunologist studying how airborne pathogens infect and alter cells in the lungs. Her work focuses in particular on a bacterium called Francisella tularensis, which causes a life-threatening disease called tularemia and has the unique ability to change how energy-producing mitochondria function in immune cells. Dr. Bosio's experiments with these deadly bacteria could lead to more effective ways to diagnose and treat tularemia and other infectious diseases.
Monday, October 7, 2019
Our blood is made up of a diverse array of different cells, all of which originate from the same source: the ‘hematopoietic’ stem cells in our bone marrow. Dr. Cynthia Dunbar is a clinician working to understand how these stem cells grow, divide, and ultimately produce the cells that carry oxygen around the body and fight disease. Learning to safely transplant and manipulate hematopoietic stem cells could lead to treatments for a wide variety of diseases caused by a lack of properly functioning blood cells, including leukemia and aplastic anemia.
Tuesday, September 10, 2019
This episode features two legends of biomedical research. In the realm of human health and longevity, cancer’s ability to mutate, grow, and thwart the body’s natural defenses presents one of the greatest scientific challenges of our time. In 2001, Dr. Ira Pastan led the creation of a new type of cancer drug, a recombinant immunotoxin, that promised to directly target and kill cancer cells. After years of research and clinical trials, this first-generation immunotoxin was approved by the FDA in September 2018 for certain adults with hairy cell leukemia, providing a promising new therapy to a group of patients who previously had few other options.
And we have a special guest host for this episode, Dr. Michael Gottesman, who, as the NIH Deputy Director for Intramural Research, leads the thousands of researchers and clinicians working within the IRP each day — while also conducting groundbreaking research in his own laboratory into how cancer cells become resistant to chemotherapy and other anti-cancer drugs. Drs. Gottesman and Pastan are two guiding lights in our quest to overcome the obstacles to effectively treating cancer in order to improve and save potentially millions of lives. As friends and colleagues for many years, they also trained and collaborated with several of the most celebrated IRP researchers who made extraordinary breakthroughs for human health.
Friday, June 28, 2019
Dr. Dori Germolec is a biologist studying how the chemicals in our environment affect the immune system, including toxic or carcinogenic effects of molds and dietary supplements. From bisphenols and flame retardants to arsenic in the drinking water and polycyclic aromatic hydrocarbons, we are all exposed to a mixture of different compounds on a daily basis. Dr. Germolec’s research as part of the National Toxicology Program informs agencies like the EPA and FDA about the potential hazards of environmental toxins so that chemicals and substances can be properly regulated to keep people safe and healthy, both at home and in the workplace.